Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients.

Daniele NapolitanoCarlo Romano SettanniLaura ParisioNicoletta OrgianaAndrea PosciaElisa SchiavoniLaura TurchiniAlessio Lo CascioFrancesco GerminiElena SblendorioAlessandra MilaniChristopher PatterilLucrezia LaterzaLoris Riccardo LopetusoDaniela PuglieseAlfredo PapaAntonio GasbarriniFranco Scaldaferri

Published in: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (2024)

The transition from in-hospital to subcutaneous therapeutic management of biological therapy at home was generally viewed favorably by patients, especially if they have commitments or were residents far from the IBD center.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
healthcare
emergency department
stem cells
high dose
patient reported outcomes
patient reported
adverse drug